Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ligand Pharmaceuticals Incorporated Trends and Insights

SG&A Expenses: Walgreens vs. Ligand - A Financial Contrast

__timestampLigand Pharmaceuticals IncorporatedWalgreens Boots Alliance, Inc.
Wednesday, January 1, 20142257000017992000000
Thursday, January 1, 20152437800022400000000
Friday, January 1, 20162662100023910000000
Sunday, January 1, 20172865300023813000000
Monday, January 1, 20183773400024694000000
Tuesday, January 1, 20194188400023557000000
Wednesday, January 1, 20206443500025436000000
Friday, January 1, 20215748300024586000000
Saturday, January 1, 20227006200027295000000
Sunday, January 1, 20235279000034205000000
Monday, January 1, 202428113000000
Loading chart...

Data in motion

SG&A Expenses: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and retail sectors, understanding the financial dynamics of key players is crucial. Walgreens Boots Alliance, Inc. and Ligand Pharmaceuticals Incorporated present a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Walgreens consistently reported SG&A expenses that were approximately 1,000 times higher than those of Ligand, reflecting its expansive retail operations. Notably, Walgreens' expenses peaked in 2024, while Ligand's expenses showed a more volatile trend, peaking in 2022. This disparity highlights the scale and operational differences between a global retail giant and a specialized pharmaceutical company. The absence of data for Ligand in 2024 suggests a potential shift or anomaly worth further exploration. As these companies navigate their respective industries, their SG&A trends offer valuable insights into their strategic priorities and market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025